Chugai Pharmaceutical has announced that the company has agreed with the Japanese government regarding the antibody cocktail- casirivimab and imdevimab, which is being investigated as a potential treatment for COVID-19. Under this agreement, the Japanese government will secure the antibody cocktail for the year 2021 for domestic supply if it is approved by the regulatory authority in Japan.
If you find a dimension intereseting, we recommend you pick up one or two facts that you find intriguing and place them into your memory. That way you will have 2nd degree information about the topic if it comes up in conversation.
Accordingly, you can do the same with others as well.